NHS transforming healthcare the journey continues
The National Health Service in England which was launched in 1948, now services nearly 1 million patients per day from cradle to grave free at the point of care, and it is recognized by many to be one of the most efficient healthcare delivery systems in the world. However, the challenges of increasing demand and the need to contain costs, requires innovative ways of thinking and new structures. Central to NHS Englands transformation plan, contained in the NHS Englands Five Year Forward View, is the development and testing of New Models of Care.
The first initiative under this plan was the selection of 50 vanguard sites to take a lead on the development of new care models across, acute care collaborations; urgent and emergency care; integrated primary and secondary care and; multispecialty community providers. Many sites focused on care beingintegrated more effectively around the needs of populations and patients, and a high priority for all the sites, was to strengthen links between general practices and other health and care services. After two years of operation, progress has been faster in some sites rather than others, but there is a common recognition of the need to do things differently, and a palpable enthusiasm to make changes.
The Test Beds programme was unprecedented in scale, with 40 innovators, 51 digital products, eight evaluation teams and five voluntary sector organisations involved. The programme is still in its testing phase, working with 51 innovations across redesigned pathways and engaging over 4,000 people. When the testing is concluded in the summer of 2018 it is anticipated that 15,000 people will have been engaged in the programme.
An important bottom up approach to driving healthcare transformation, has been the development of sustainability and transformation plans (STPs) by health and social care leaders, to reflect the needs of specific geographical regions. The plans developed in 44 regions (submitted in October 2016) were required to cover three broad themes: improving quality and developing new models of care; improving health and wellbeing and; improving efficiency of services.
It is widely believed that this approach is the only practical way to bring about sustainable change, and a recent report on four STPs, provided recommendations for refinement in the future, including securing more meaningful involvement of patients and the public in the plans, and focusing on the skills and resources needed to implement STPs, as well as the cultural aspects of making change happen.
NHS England, like many other healthcare delivery systems have been wrestling with the challenge of how to ensure that patients benefit from technology advances at the earliest opportunity. The publication of the Accelerated Access Review Report late in 2016 after an extensive consultation period engaging all major stakeholders including industry, provided fresh momentum to responding to this challenge. Included in its recommendations were:
i) A new transformative designation should be applied to those innovations with the potential for greatest impact
ii) Accelerated Access Pathway should be created for strategically important, transformative products
iii) National routes to market should be streamlined and clarified
iv) a range of incentives should support the local uptake and spread of innovation, enabling collaboration and with greater capacity and capability for change.
and Technology Tariff
Turning to support for companies developing new innovative products, since 2008 the NHS has backed a Small Business Research & Innovation programme (SBRI), which has supported more than100 companies to develop innovative technologies that match the specifi c priority needs identifi ed in competition calls. This provides 100% funding for SME-led collaborations to develop solutions to real needs. A recent independent report commissioned by the NHS has demonstrated significant benefi ts of the programme not only in respect to improved performance and cost savings, but also in respect to economic impact with regard to increase jobs, export sales and investment leveraged.
The National Institute of Health Research (NIHR) infrastructure offers signifi cant support for companies that are seeking to undertake clinical trials in the UK, this support spans advice on the use of specialist clinical research networks (e.g. cardiovascular disease), regulation, costing, site identifi cation, recruitment, optimizing delivery, effi cient study set up and performance monitoring. This enables companies to fast track clinical study execution.
Strengthening ties between the UK and the Middle East
One again, the Association of British Healthcare Industries (ABHI) are delighted to be the official organiser of the UK pavilion at Arab Health 2018. As the UKs leading Medical Technology trade association, we are well positioned to showcase the best in cutting-edge MedTech innovation that our country has to offer. With 200 UK companies exhibiting at Arab Health in January, we are excited with the sheer breadth and diversity of the technologies on display. It is a wonderful expression of what our industry has to offer in providing value-based healthcare solutions for patients across the globe.
As most will be aware, the UK is experiencing unprecedented change as it navigates its exit from the European Union. Yet despite this, the MedTech sector remains undeterred. It continues to grow at both pace and scale, and is now worth over £17 billion to the UKs economy. The industry remains resolute and is actively seeking opportunities post-Brexit.
With Brexit in mind, the UK Government has launched an Industrial Strategy to drive the country forward. As part of this, Life Sciences has repeatedly been highlighted as a key area for future growth, and MedTech identified as a pillar of this strategy. We believe that trade will be vital in enabling this vision to become a reality.
ABHI has, for a long time, offered UK companies a variety of support and opportunities to export globally. International membership is making these links more accessible for international companies wanting to partner with their British counterparts. We are signposting and introducing international companies to a highly-developed network within the UK health system with a view to supporting the development of jointventures and distribution agreements. As well as access to written briefings, webinars and market intelligence reports, membership is underpinned by the collective expertise of ABHIs senior leadership team and the international division of the association. Some companies may even already have activities within the UK, but are looking for that next step, which is where we are able to provide the assistance needed.
We are delighted to already have several international members on board. A number of these hail from the Middle East, a region we consider to be very much a priority for our association and our membership. We have been bringing UK companies to Arab Health for a number of years and the show continues to go from strength to strength. No longer can the Middle East be considered an emerging market. It's position as a key global player in the healthcare sphere must be recognised.
With the UK's medical expertise and the rising number of Middle Eastern patients visiting our world-class clinics, we are eager to deepen these relationships further. We believe the UK is a great place for both healthcare and business and as our international membership develops we are looking forward to developing these relationships with the Middle East further.
New surgical approach for total hip replacement allows faster rehabilitation, no muscle damage
Recently there has been an increase in interest in performing hip replacement surgery by less invasive means, and by smaller incisions. Some of these so called minimally invasive techniques however are only reduced skin incision techniques and are associated with the same muscle and/or tendon injury as conventional approaches.
AMIS® (Anterior Minimally Invasive Surgery) is a surgical technique used in total hip replacement procedures which follows an inter-muscular and inter-nervous plane to reduce the risk of injury to muscles, tendons, vessels and nerves. By respecting the nerves and because no muscles are cut, this aids rapid recovery for patients following surgery.
What are the advantages?
What are the disadvantages?
Does it make a difference
in the long-term?
At the Royal National Orthopaedic Hospital the AMIS Total Hip replacement is being offered by Mr Panos Gikas, who has done a postgraduate fellowship at the University Hospital of Geneva on this approach.
Innovative lung volume coil reduces severe emphysema symptoms
Royal Brompton and Harefield Hospitals Specialist Care provide pioneering diagnostics and treatment to international patients with heart and lung conditions. Many of our consultants are world leaders in their field and offer some of the most sophisticated treatment available anywhere across the globe.
Early this year a new innovative service was launched at the Royal Brompton and Harefield Hospitals in London, UK to treat severe emphysema patients. Lung volume reduction coils are implanted into the diseased parts of the patients lung during a minimally invasive bronchoscopy procedure, typically taking only 30-45 minutes per procedure. Treatment involves two separate procedures, for each lung, 4-6 weeks apart. This treatment helps to reduce hyperinflation in severe emphysema patients, resulting in a reduction in difficult or laboured breathing.
The PneumRx® Coils are made of a shape-memory material called Nitinol, common in medical implants such as heart stents. The PneumRx® coils are implanted into the airways via a catheter, and once in place are designed to gently regain their shape, gathering up loose, inelastic lung tissue and holding open surrounding airways. Ten or more coils are placed at each procedure to tighten the entire airway network and achieve the optimal effects.
The coils improve lung function in three ways. Firstly, they compress diseased tissue, which provides room for healthier tissue to function; secondly, they re-tension adjacent parenchyma, helping to increase the lungs elasticity, which may enable the lung to more efficiently contract during the breathing cycle; finally, the coil tethers open small airways, preventing airway collapse during exhalation.
Dr Samuel Kemp, Royal Brompton Hospital respiratory physician who performs the treatment says: Patients with emphysema often have disabling breathlessness which does not respond significantly to drug therapy. Lung volume reduction coil treatment can offer relief from some of these symptoms, giving patients an improvement in quality of life.
Following the procedure a patient can typically return home after just one night in the hospital and see results almost immediately. Patients treated with coils may experience significant improvement in exercise capacity, lung function and quality of life.
|Date of upload: 19th Nov 2017|
Copyright © 2017 MiddleEastHealthMag.com. All Rights Reserved.